Skip to main content

NCT02385058 - Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthias

Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population


CSR Summary

Not Available


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Mebendazole
Product Name
VERMOX
Therapeutic Area
Parasitic Diseases
Enrollment
100
% Female
N/A
% White
N/A
Product Class
Antiparasitics
Sponsor Protocol Number
MEBENDAZOLGAI3001
Data Partner
Johnson & Johnson
Condition Studied
Helminth Infections
Mean/Median Age (Years)
N/A

Supporting Documentation

Clinical Study Report
Study Phase 
4
Additional Information: 

Please note: individual participant-level data are not available for this trial. Only the full clinical study report is available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.